Press releases | WebDisclosure

Basculer en Français

9561	Companies
188876	Keywords
120603	Articles
100796	Press releases

Home
Press releases

PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 2 months ago

XS Financial Expands Into Middle-Market Equipment Finance, Establishing Buy-Side Capital Markets Desk
XS Financial announces strategic expansion into mid to large-ticket transactions in middle-market equipment leasing sector. Acquired by Axar and Mavik, enhancing financial strength and flexibility

Expansion Capital Markets Equipment Finance XS Financial Middle-Market
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 2 months ago

LQR House Inc. Implements Strategic Cost-Cutting Measures Under Activist Investor David Lazar's Leadership
LQR House Inc. announces strategic updates including shutting down RareSips NFT platform and ending Bevage LLC partnership under new Director David Lazar to enhance operational efficiency and shareholder value

LQR House Inc. Operational Efficiency Shareholder Value Strategic Updates David Lazar
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 2 months ago

Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
Catheter Precision announces publication on non-invasive ablation technique STAR for cardiac electrophysiology. VIVO technology shows promising results in targeting heart arrhythmia areas

Catheter Precision Cardiac Electrophysiology VIVO Technology STAR Ablation Technique
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 2 months ago

Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD
Inventiva annonce un abstract "late breaker" sur l'essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine lors du Liver Meeting™ 2024 organisé par l'AASLD

Essai Clinique Inventiva Lanifibranor Abstract Empagliflozine
PRESS RELEASE

published on 10/21/2024 at 14:30, 1 year 2 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces late breaker abstract from LEGEND Phase 2 trial evaluating lanifibranor with empagliflozin in MASH at AASLD The Liver Meeting® 2024

Inventiva MASH Lanifibranor LEGEND Phase 2 Empagliflozin
PRESS RELEASE

published on 10/21/2024 at 14:25, 1 year 2 months ago

Director/PDMR Shareholding
Britvic plc Directors purchase shares and receive matching shares under Share Incentive Plan. Details of transactions and interests disclosed

Transactions Share Incentive Plan Britvic Plc Directors Matching Shares
PRESS RELEASE

published on 10/21/2024 at 14:15, 1 year 2 months ago

Quant Tekel: Defining the Future of Trading
Quant Tekel revolutionizes brokerage and prop trading with cutting-edge technology, unmatched experience, and top-tier support for traders, offering opportunities for success and personal growth

Cutting-edge Technology Financial Markets Brokerage Prop Trading Quant Tekel
PRESS RELEASE

published on 10/21/2024 at 14:01, 1 year 2 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed reports 4% revenue increase in Mid-Year 2024 Financial Results with 32% decrease in loss from operations. Company highlights successful studies at ASCO and outlines strategic plan for 2025

Financial Results Corporate Update ColoAlert Mainz Biomed EAArly DETECT
PRESS RELEASE

published on 10/21/2024 at 14:00, 1 year 2 months ago

CANEX Increases Equity Financing
CANEX Metals Inc. announces increase in non-brokered private placement to offer up to 3,000,000 Common Shares and 5,250,000 FT Shares for a total of $450,000. Funds to be used for exploration and project advancement

Private Placement TSX Venture Exchange Exploration CANEX Metals Inc. Shareholder Demand
PRESS RELEASE

published on 10/21/2024 at 13:30, 1 year 2 months ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD

Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 12/20/2025 at 00:30, 2 days 7 hours ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 2 days 9 hours ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days 13 hours ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 17 hours ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 2 days 18 hours ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE

EQS Group

Published on 12/22/2025 at 07:30, 13 minutes ago

EUROPLASMA: KNDS France renouvelle son engagement auprès des Forges de Tarbes
Published on 12/22/2025 at 07:30, 13 minutes ago

Mutares signs an agreement to acquire the Gas Solutions business from Wärtsilä
Published on 12/22/2025 at 07:00, 43 minutes ago

VIB Vermögen AG sells logistics property in Großmehring
Published on 12/22/2025 at 04:30, 3 hours 13 minutes ago

DFSK Officially Enters the Egyptian Market with Strategic Vehicle Lineup
Published on 12/22/2025 at 00:35, 7 hours 8 minutes ago

Samsung to Host Series of Tech Forums at CES 2026

Les Echos

Published on 12/19/2025 at 21:57, 2 days 9 hours ago

Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 2 days 23 hours ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 2 days 23 hours ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 3 days ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 3 days ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE